So the cash burn of the company is something that has been shrinking quite a bit. And we anticipate, as I said earlier, getting to a place of breakeven and profitability within 12 months. depending upon the timing of what the FDA has to offer us and looking at the pipeline of customers and systems that we have, that number could be sooner. I don’t want to speculate on exactly when it’s very, very hard to forecast these things. We’ve been seeing an increasing number of sales and, of course, the revenue associated with every one of those sales is going up. As I said, we just increased our prices by 20%. And the absolute number of sales is going up a lot, too. So these are all the kind of things that to see happening. Let’s see. — didn’t okay, a very detailed set of questions.
Let’s see. Has the kit revenue rate increased because of new accounts or because of increased utilization from existing customers. We’ve seen an increase in the utilization rates from increasing customers. So for example, we’ve seen certain physicians increase their utilization due to our outreach because of initiatives around customer education, grand rounds, those sorts of things. But we’ve also been spreading more within a hospital system. In other words, getting other clinicians to utilize the test and make it part of their centered on their care. We’ve also been adding customers and new accounts as well, too. So it’s really a combination of both of those things. Another question was, I’m interested to learn what milestones Daxor has to do to complete to lend an additional $2.5 million of DoD funding.
The answer is we don’t have to do any more additional work on that. We’re anticipating receiving some news around those contracts in the next four to eight weeks. And we’ve done a substantial number of these contracts in the past with the DoD. It’s been an honor to work with them and we’ll update shareholders as soon as we know more around that. Let’s see. How much more does the quarterly revenue run rate have to increase for you to reach breakeven. So — and how much of this is assumed based upon the FDA approval of the new device. So again, our forecast of breakeven within that time frame. Our anticipation around that is based upon the increased utilization rate that we’re seeing with the existing systems, that’s a BVA-100 along with the ezBVA lab and anticipation around the being the recipient of certain contracts and grants as well.
But it’s not predicated upon a specific approval date of system that’s under review right now, which is the so-called next-generation BVA system. Were we to receive that approval sooner rather than later than we think that, that would help us to accelerate that time line. of breakeven and profitability. So I think it’s going to be quite important for us. Let’s see. A question — what is the reason that tax was involved in investing in stocks on financial vehicles, would it be better focused on the BVA business. We are focused actually almost entirely on our operating business, the background for investors who aren’t aware is that the company has a long history of being in the lab services business. We were also a very profitable company over those years, we had invested or retained earnings into a series of interest rate bearing securities, and the SEC determined that they wanted investors to have more visibility into those investments.
That’s why the company was then asked to file under a 40x status. One of the things that’s interesting for people who follow the company, we’ve been a publicly traded company, I believe in 1971. We went public with 5 million shares. We actually have a lower share count now than when we went public over 50 years ago. That’s because the company over the years was not only profitable, we engaged in a lot of share buybacks over that time period. We’ve been very, very selective about raising capital in those intervening years, 1986 was one of the last times that we raised money between which was going public and was an exon that we raised money. And then after 1986, the next time that we raised money was in 2020. So we’re — management is really intensely focused on creating shareholder value.
We have raised money in order to fund the development of our next-generation systems, all of the IP work all of the different things that you’ve been hearing about on this call. But we still have a very, very clean cap table. We don’t have any warrants or derivatives outstanding management is really focused on building the company in a very shareholder-friendly way. Let’s see . What is the U.S.A. Army waiting for to purchase the newest BVA? So the United States Army generally will only purchase FDA-approved products for its use, either with the military or within BVA system. We have lead volume analyzers in use in the veterans administration system right now. There is our BVA-100 unit. As soon as the next-generation system is available with a proper FDA clearance, then that would be something that we could consider to use.
But I want to be clear with people that the largest opportunity and it is a really substantial opportunity. Just look at critical care, things like sepsis, with several million patients a year alone, and fluid management is at the center of that care. The largest opportunity for us is not necessarily in military medicine per se, although that is an opportunity really in civilian and that’s really a very substantial market to address. Somebody also asked, are there any research coverage prospects will be that depending on costs in less? No, actually, Daxor is covered by analysts. They do issue independent research reports right now. suppose you should be in touch with our Investor Relations people, they can point in the right way, but there is coverage by, I believe, the investment bank Maxim as well as Ascendiant Capital Markets amongst others.